GlassScriptPhysician profile
Reshma M Shah
NPI 1194771527
$676.81
in general payments reported to CMS, 2019-2025
18 companies · $43.23 in 2025
The $43.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $86.70 · 2021: $128 · 2022: $102 · 2023: $198 · 2025: $43.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $129.77 | 2020-2023 | Saxenda, Wegovy |
| Merck Sharp & Dohme LLC | $72.69 | 2019-2021 | |
| Insulet Corporation | $65.40 | 2023 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $42.87 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.06 | 2019-2025 | Jardiance |
| Abbott Laboratories | $40.71 | 2023 | Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $36.76 | 2022-2023 | Gvoke Hypopen |
| Pfizer INC. | $36.65 | 2021-2023 | |
| Glaxosmithkline, LLC. | $36.25 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $21.60 | 2025 | |
| Esperion Therapeutics, INC. | $21.20 | 2021 | |
| Ibsa Pharma INC. | $20.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.31 | 2021 | |
| Abbvie INC. | $19.99 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $19.97 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.43 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.55 | 2023 | Rexulti |
| Gilead Sciences, INC. | $16.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.